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diseese (all n=l) and an EF of 44 f 16 %. 7/21 pts had only 
recurrent VT but no VF. During preimplantation EP-study in 6 
pts an induced slow (5 260 bpm) VT could be terminated by 
antitachycardia pacing (ATP). During implantation, sensin 
cing thresholds and termination of VF were tested, but no 
for VT. Postoperatively, 2 pts died of pulmonary complications. 
Before hospital discharge, an EP-study was performed via PCD 
telemetry assuring proper function of the PCD. While a fast (a 
2OOlmin) VT (67 44 of pts) or VF (50 % of pts) could be induced 
in all pts, a stow VT was only induced (and terminated by ATP) in 
218 pts with preimplant induced VT susceptible to ATP. Still in all 
6 pts ATP was activated as the first therapy for 
follow-up (5 f 3 months) 10119 pts experi 
recurrences. In 418 pts with activated ATP functi 
a cycle lengths of 395 f 62 ms were terminated 
episodes were neither terminated nor accelerated by ATP but 
successfully treated by subsequent cardioversion. In 1 VT- 
caused an acceleration from 360 to 220 ms 
Ily treated by a defibrillation shock. In 7 pts 1 
cyclelengths of 251 f 23 ms were terminated by 
defibrillation shocks. No pt experienced a syncope. 2 pts 
not aware of their VT-episodes due to early termination by 
One pt died due to progressive heart failure after 4 months. 
Thus, ATP provided by the PCD reduces the number of 
shocks for VT in sudden cardiac death survivors and 
detibrillation back-up by the PCD allows ATP in pts with VT onty. 
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AUTOMATIC DEFIBRILLATOR I PLANTATION USING A TRANSVENOUS 
ELECTRODE SYSTEM THAT INCLUDES THE COR 
, George J. Klein, James W. L&h, Gerard 
Norris, University Hospital. London, Ontario, Canada 
We report our experience with a new non-thoracotomy lead system far 
automatic delibrillator implantation. Three transvenous defibrillating 
electrodes were inserted percutaneously into the lett subclavian vein and 
positioned in the RV apex , superior vena cava (SVC) and coronary sinus 
(CS), respectivety. Leads were tunnelled subcutaneously and connected to 
the generator implanted in the eptgastrtum. Criteria for implantation included 
an lntraoperative defibrillation threshold of 518 Joules (J) using the 
sequential pulse technique. 
Eleven pts had known 
ventricular tachycardia 
VTNF In one other. L 
(mean X9*1%). Seve 
defibrillation threshold 
thoracotomy defibrillation 
defibrillation threshold us 
unacceptably high 
shocks 01 30 - 34 J were delivered. There were no spontaneous VT 
episodes that received shocks to terminate. Overt 
has been no evidence of electrode mattunctton, d 
effects horn coronary sinus shocks. One pt died of respiratory failure. At 
autopsy, there was no evidence 01 damage to the CS or left circumflex artery 
lrom repeated transvenous defibrillatory shocks. In conclusion, a 
transvenous lead system involving the coronary slnus for automatic 
defbrillator imptantatttn represents a viable, safe and effective approach that 
avoids a thoracotomy. 
tomy: a subcutaneous patch (anode) near the cardiac apex, a 
transvenous lead (anode) in the superior vena cava (n=6) or the 
coronary sinus (t-+4) and a transvenous pacing /defibrillation 
lead (cathode) screwed into the right ventricle. The implantation 
was done under general anaesthesia (221 & 79 min) using a 
single X-ray source to position all leads (IS f 10 min). To obtain 
sufficient sensing (R-amplitude = 13 f4 mV; slew rate = 1.6 f 
0.6 V/s) and pacing (threshold at 0.5 ms = 1.0 f 0.4 V) the 
pacing/defibrillation lead had to be repositioned in 7 cases 1 - 8 
times. Defibrillation threshold (DFT) tssting required 9 f 4 
episodes of ventricular fibrillation, 14 f 8 shocks and lasted 69 f. 
51 min. With the first configuration using a superior vena cava 
anode and sequential dual shock pathways, 6 pts had a 
sufficient DFT (SW). In 5 pts sufficient (n=3) or borderline (n=2) 
DFT were achieved by using a coronary sinus position (n=2), a 
single shock pathway (n=2) or a ditOer8ni subcutaneous patch 
postion (n=l), while 1 pt had a borderline DFT and 1 pt an 
insufficient (no implant) DFT in all configurations. Postoperative 
ly, hematomas occurred in 2 pts and after 
the subcutaneous lead in 1 pt. During fo 
chest-x-rays, EP-studies and termination 
des in 5 pts revealed no dislocation or dysfunction of the leads. 
Thus, transvenous-subcutaneous implantation of PCD-leads 
is a safe procedure.The succe ral differ 
lead configurations are tested. has SD70 
no defect, dislocation or loss of function of the lead system. 
